Trial Outcomes & Findings for Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms (NCT NCT00666926)
NCT ID: NCT00666926
Last Updated: 2013-03-21
Results Overview
At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) for \>7 days or Gr 3 febrile neutropenia (ANC \<1000/mm\^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets \<25,000 cells/mm\^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (\>500 milliseconds \[msec\]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
99 participants
Primary outcome timeframe
Baseline up to Cycle 1 Day 21 (C1.D21)
Results posted on
2013-03-21
Participant Flow
Expansion cohort (E1 or E2): participants were to be those enrolled at maximum tolerated dose level. E1: to have advanced disease likely to possess functional aberrations of pathways for tumorigenesis (represent focal adhesion kinase \[FAK\] expression). E2: to have disease characteristics associated with FAK expression and agree to repeat biopsies.
Participant milestones
| Measure |
PF-00562271 5 mg BID
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 (C1.D21) simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
2
|
4
|
3
|
4
|
3
|
4
|
4
|
1
|
3
|
10
|
6
|
33
|
3
|
4
|
7
|
8
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
2
|
4
|
3
|
4
|
3
|
4
|
4
|
1
|
3
|
10
|
6
|
33
|
3
|
4
|
7
|
8
|
Reasons for withdrawal
| Measure |
PF-00562271 5 mg BID
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 (C1.D21) simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
0
|
1
|
0
|
0
|
|
Overall Study
Laboratory abnormality
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Lack of Efficacy
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Other
|
2
|
4
|
3
|
3
|
3
|
3
|
4
|
0
|
3
|
5
|
3
|
26
|
3
|
2
|
4
|
4
|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
3
|
0
|
3
|
0
|
1
|
3
|
3
|
|
Overall Study
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Baseline characteristics by cohort
| Measure |
Entire Study Population
n=99 Participants
PF-00562271 dose escalation administered as 5 mg PO BID up to 150 mg PO BID or 125 mg PO QD up to 225 mg PO QD. Participants in the PF-00562271125 mg BID US E1 cohort administered MDZ 2 mg/mL as a single dose on C1.D1 and C1.D21 prior to PF-00562271 dosing.
|
|---|---|
|
Age Continuous
|
58.7 years
STANDARD_DEVIATION 11.3 • n=93 Participants
|
|
Sex: Female, Male
Female
|
43 Participants
n=93 Participants
|
|
Sex: Female, Male
Male
|
56 Participants
n=93 Participants
|
PRIMARY outcome
Timeframe: Baseline up to Cycle 1 Day 21 (C1.D21)Population: Safety analysis set: All enrolled participants who started treatment.
At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) for \>7 days or Gr 3 febrile neutropenia (ANC \<1000/mm\^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets \<25,000 cells/mm\^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (\>500 milliseconds \[msec\]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=1 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=10 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=6 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=33 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=3 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=4 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=7 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=8 Participants
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
1 participants
|
1 participants
|
2 participants
|
0 participants
|
1 participants
|
1 participants
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline, C1.D14Population: Participants in the 125 mg BID expansion cohort with at least 1 dose of study treatment, at least 1 lesion with an SUV ≥5 at baseline, and an on-study PET assessment C1.D14 (Day 13 up to Day 17).
Metabolic response demonstrated in any tumor reduction of ≥15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of ≥5.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=14 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)
|
50 percentage of participants
Interval 26.4 to 73.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 morning (am) dosePopulation: Pharmacokinetic (PK) parameter analysis set: all participants with at least 1 dose of study treatment and at least 1 of the PK parameters of interest estimated in at least 1 treatment period. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=6 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=8 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=1 Participants
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
n=4 Participants
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
n=11 Participants
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Serum Concentration (Cmax): PF-00562271 C0.D1, C1.D1
|
49.63 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 4
|
71.13 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 24
|
138.8 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 73
|
130.1 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 176
|
306.1 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 28
|
312.9 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 108
|
363.2 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 37
|
597.6 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 2
|
397.3 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 91
|
1018 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 48
|
1236 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 49
|
647.2 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 52
|
1110 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 35
|
1528 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 57
|
2605 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 35
|
421.0 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 0
|
474.6 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 44
|
747.9 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 75
|
SECONDARY outcome
Timeframe: Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dosePopulation: PK parameter analysis set
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=3 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=4 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=4 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=2 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=5 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=4 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Serum Concentration (Cmax): PF-00562271 C1.D14
|
74.65 ng/mL
Geometric Coefficient of Variation 80
|
134.7 ng/mL
Geometric Coefficient of Variation 55
|
309.6 ng/mL
Geometric Coefficient of Variation 58
|
307.7 ng/mL
Geometric Coefficient of Variation 145
|
655.4 ng/mL
Geometric Coefficient of Variation 72
|
1105 ng/mL
Geometric Coefficient of Variation 46
|
1083 ng/mL
Geometric Coefficient of Variation 84
|
1767 ng/mL
Geometric Coefficient of Variation 61
|
2295 ng/mL
Geometric Coefficient of Variation 74
|
2580 ng/mL
Geometric Coefficient of Variation 62
|
2947 ng/mL
Geometric Coefficient of Variation 62
|
3445 ng/mL
Geometric Coefficient of Variation 65
|
2021 ng/mL
Geometric Coefficient of Variation 17
|
3136 ng/mL
Geometric Coefficient of Variation 43
|
4438 ng/mL
Geometric Coefficient of Variation 49
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dosePopulation: PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=6 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=8 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=1 Participants
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
n=4 Participants
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
n=11 Participants
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C0.D1, C1.D1
|
0.500 hours
Interval 0.5 to 0.5
|
1.50 hours
Interval 1.0 to 2.0
|
0.500 hours
Interval 0.5 to 1.0
|
0.500 hours
Interval 0.5 to 0.5
|
1.00 hours
Interval 0.5 to 2.0
|
1.50 hours
Interval 1.0 to 4.0
|
1.00 hours
Interval 1.0 to 2.0
|
2.00 hours
Interval 0.5 to 8.0
|
4.00 hours
Interval 4.0 to 4.0
|
2.00 hours
Interval 0.5 to 6.0
|
4.00 hours
Interval 0.5 to 8.0
|
4.00 hours
Interval 0.5 to 8.0
|
5.00 hours
Interval 4.0 to 6.0
|
4.00 hours
Interval 2.0 to 6.0
|
4.00 hours
Interval 2.0 to 6.0
|
4.00 hours
Interval 4.0 to 4.0
|
6.00 hours
Interval 4.0 to 8.0
|
4.00 hours
Interval 1.0 to 4.0
|
SECONDARY outcome
Timeframe: Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dosePopulation: PK parameter analysis set
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=3 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=4 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=4 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=2 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=5 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=4 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C1.D14
|
0.500 hours
Interval 0.5 to 0.5
|
1.00 hours
Interval 0.5 to 2.0
|
1.00 hours
Interval 1.0 to 8.0
|
1.50 hours
Interval 0.5 to 4.0
|
2.00 hours
Interval 2.0 to 12.0
|
1.00 hours
Interval 0.5 to 4.0
|
1.50 hours
Interval 1.0 to 4.0
|
2.00 hours
Interval 1.0 to 2.0
|
2.25 hours
Interval 0.0 to 12.0
|
3.00 hours
Interval 0.5 to 4.0
|
4.00 hours
Interval 0.0 to 12.0
|
7.00 hours
Interval 6.0 to 8.0
|
5.00 hours
Interval 2.0 to 8.0
|
2.00 hours
Interval 2.0 to 4.0
|
2.50 hours
Interval 0.5 to 8.0
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dosePopulation: PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
Area under the serum concentration time-curve from zero to the last measured concentration; nanograms multiplied by hours per milliliters (ng\*hr/mL).
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=6 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=8 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-00562271 C0.D1, C1.D1
|
81.13 ng*hr/mL
Geometric Coefficient of Variation 47
|
233.8 ng*hr/mL
Geometric Coefficient of Variation 14
|
348.1 ng*hr/mL
Geometric Coefficient of Variation 67
|
295.6 ng*hr/mL
Geometric Coefficient of Variation 213
|
1205 ng*hr/mL
Geometric Coefficient of Variation 6
|
2364 ng*hr/mL
Geometric Coefficient of Variation 118
|
1735 ng*hr/mL
Geometric Coefficient of Variation 67
|
4407 ng*hr/mL
Geometric Coefficient of Variation 42
|
3501 ng*hr/mL
Geometric Coefficient of Variation 171
|
10600 ng*hr/mL
Geometric Coefficient of Variation 61
|
11900 ng*hr/mL
Geometric Coefficient of Variation 163
|
6083 ng*hr/mL
Geometric Coefficient of Variation 134
|
16330 ng*hr/mL
Geometric Coefficient of Variation 12
|
20830 ng*hr/mL
Geometric Coefficient of Variation 66
|
38600 ng*hr/mL
Geometric Coefficient of Variation 78
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dosePopulation: PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=3 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=2 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=5 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=3 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=6 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): PF-00562271 C0.D1, C1.D1
|
86.24 ng*hr/mL
Geometric Coefficient of Variation 48
|
239.6 ng*hr/mL
Geometric Coefficient of Variation 14
|
354.1 ng*hr/mL
Geometric Coefficient of Variation 68
|
574.1 ng*hr/mL
Geometric Coefficient of Variation 18
|
1222 ng*hr/mL
Geometric Coefficient of Variation 6
|
2399 ng*hr/mL
Geometric Coefficient of Variation 118
|
1759 ng*hr/mL
Geometric Coefficient of Variation 66
|
4507 ng*hr/mL
Geometric Coefficient of Variation 44
|
6588 ng*hr/mL
Geometric Coefficient of Variation 65
|
10880 ng*hr/mL
Geometric Coefficient of Variation 71
|
5534 ng*hr/mL
Geometric Coefficient of Variation 271
|
6101 ng*hr/mL
Geometric Coefficient of Variation 135
|
16770 ng*hr/mL
Geometric Coefficient of Variation 13
|
21190 ng*hr/mL
Geometric Coefficient of Variation 65
|
37560 ng*hr/mL
Geometric Coefficient of Variation 87
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dosePopulation: PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
Serum decay half-life is the time measured for the serum concentration to decrease by one half.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=3 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=2 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=5 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=3 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=6 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Serum Decay Half-life (t 1/2): PF-00562271 C0.D1, C1.D1
|
1.990 hours
Standard Deviation 0.60811
|
2.078 hours
Standard Deviation 0.40901
|
2.173 hours
Standard Deviation 0.38799
|
2.837 hours
Standard Deviation 1.2176
|
2.897 hours
Standard Deviation 0.53304
|
5.270 hours
Standard Deviation 1.8993
|
3.365 hours
Standard Deviation 0.88410
|
4.770 hours
Standard Deviation 0.51069
|
5.025 hours
Standard Deviation 0.62933
|
6.180 hours
Standard Deviation 2.9592
|
3.853 hours
Standard Deviation 1.4332
|
4.407 hours
Standard Deviation 1.9318
|
8.388 hours
Standard Deviation 1.9370
|
5.937 hours
Standard Deviation 1.1016
|
7.948 hours
Standard Deviation 2.7254
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dosePopulation: PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=3 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=3 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=2 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=5 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=3 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=7 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=6 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Oral Clearance (CL/F): PF-00562271 C0. D1, C1.D1
|
964.2 milliliters per minute (mL/min)
Geometric Coefficient of Variation 48
|
702.1 milliliters per minute (mL/min)
Geometric Coefficient of Variation 17
|
707.2 milliliters per minute (mL/min)
Geometric Coefficient of Variation 68
|
726.0 milliliters per minute (mL/min)
Geometric Coefficient of Variation 18
|
478.0 milliliters per minute (mL/min)
Geometric Coefficient of Variation 6
|
312.3 milliliters per minute (mL/min)
Geometric Coefficient of Variation 118
|
568.3 milliliters per minute (mL/min)
Geometric Coefficient of Variation 66
|
295.5 milliliters per minute (mL/min)
Geometric Coefficient of Variation 44
|
253.2 milliliters per minute (mL/min)
Geometric Coefficient of Variation 64
|
160.9 milliliters per minute (mL/min)
Geometric Coefficient of Variation 71
|
475.5 milliliters per minute (mL/min)
Geometric Coefficient of Variation 553
|
516.9 milliliters per minute (mL/min)
Geometric Coefficient of Variation 120
|
124.0 milliliters per minute (mL/min)
Geometric Coefficient of Variation 13
|
137.7 milliliters per minute (mL/min)
Geometric Coefficient of Variation 65
|
99.85 milliliters per minute (mL/min)
Geometric Coefficient of Variation 87
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dosePopulation: PK parameter analysis set
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=3 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=4 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=4 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=2 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=5 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=4 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Minimum Observed Serum Trough Concentration (Cmin): PF-00562271 C1.D14
|
0.01349 ng/mL
Geometric Coefficient of Variation NA
Geometric CV % was not calculated for treatment groups with N \<3.
|
0.8059 ng/mL
Geometric Coefficient of Variation 12668339981
|
48.96 ng/mL
Geometric Coefficient of Variation 89
|
33.11 ng/mL
Geometric Coefficient of Variation 1046
|
145.8 ng/mL
Geometric Coefficient of Variation 131
|
315.3 ng/mL
Geometric Coefficient of Variation 112
|
359.8 ng/mL
Geometric Coefficient of Variation 80
|
594.5 ng/mL
Geometric Coefficient of Variation 134
|
1005 ng/mL
Geometric Coefficient of Variation 117
|
1131 ng/mL
Geometric Coefficient of Variation 67
|
1253 ng/mL
Geometric Coefficient of Variation 86
|
0.4111 ng/mL
Geometric Coefficient of Variation NA
Geometric CV % was not calculated for treatment groups with N \<3.
|
439.6 ng/mL
Geometric Coefficient of Variation 48
|
634.7 ng/mL
Geometric Coefficient of Variation 92
|
1129 ng/mL
Geometric Coefficient of Variation 123
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dosePopulation: PK parameter analysis set
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=3 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=4 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=4 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=7 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=2 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=4 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=5 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=2 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to the End of the Dosing Interval (AUCtau): PF-00562271 C1.D14
|
156.3 ng*hr/mL
Geometric Coefficient of Variation 53
|
447.2 ng*hr/mL
Geometric Coefficient of Variation 122
|
1573 ng*hr/mL
Geometric Coefficient of Variation 80
|
1476 ng*hr/mL
Geometric Coefficient of Variation 238
|
4519 ng*hr/mL
Geometric Coefficient of Variation 84
|
8357 ng*hr/mL
Geometric Coefficient of Variation 61
|
8173 ng*hr/mL
Geometric Coefficient of Variation 74
|
12920 ng*hr/mL
Geometric Coefficient of Variation 86
|
20010 ng*hr/mL
Geometric Coefficient of Variation 76
|
21120 ng*hr/mL
Geometric Coefficient of Variation 62
|
24340 ng*hr/mL
Geometric Coefficient of Variation 77
|
26200 ng*hr/mL
Geometric Coefficient of Variation 22
|
24470 ng*hr/mL
Geometric Coefficient of Variation 30
|
43140 ng*hr/mL
Geometric Coefficient of Variation 50
|
68780 ng*hr/mL
Geometric Coefficient of Variation 71
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Escalation (Esc) cohort: C0.D1: 0 hr, and 0.5, 1, 2, 4, 6, 7,12 hrs post dose; Expansion (Exp) cohort: C0:D1: 0 hr, and 1, 2, 4, 8 hrs post dose; Esc and Exp cohorts: C1.D14 0 hour, and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dosePopulation: PK parameter analysis set
Rac was the ratio of the Day 14 AUC0-tau (0 hour to last dose interval) and AUC during the corresponding time period after the lead-in dose (AUCtau C1.D14/AUCtau C0.D1).
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=3 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=3 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=3 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=4 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=5 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=3 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=5 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=2 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Observed Accumulation Ratio (Rac): PF-00562271 C1.D14
|
1.864 ratio
Geometric Coefficient of Variation 4
|
2.997 ratio
Geometric Coefficient of Variation 26
|
4.522 ratio
Geometric Coefficient of Variation 50
|
5.061 ratio
Geometric Coefficient of Variation 66
|
3.899 ratio
Geometric Coefficient of Variation 80
|
5.038 ratio
Geometric Coefficient of Variation 125
|
5.060 ratio
Geometric Coefficient of Variation 99
|
3.638 ratio
Geometric Coefficient of Variation 45
|
5.581 ratio
Geometric Coefficient of Variation 57
|
2.967 ratio
Geometric Coefficient of Variation 18
|
3.608 ratio
Geometric Coefficient of Variation 49
|
1.961 ratio
Geometric Coefficient of Variation 20
|
2.293 ratio
Geometric Coefficient of Variation 52
|
1.118 ratio
Geometric Coefficient of Variation 60
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Serum Concentration (Cmax): MDZ
C0.D1 (n=11)
|
13.14 ng/mL
Geometric Coefficient of Variation 47
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Maximum Serum Concentration (Cmax): MDZ
C1.D21 (n=8)
|
20.40 ng/mL
Geometric Coefficient of Variation 31
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
Area under the serum concentration time-curve from zero to the last measured concentration.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ
C0.D1 (n=11)
|
42.44 ng*hr/mL
Geometric Coefficient of Variation 53
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ
C1.D21 (n=8)
|
134.0 ng*hr/mL
Geometric Coefficient of Variation 22
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ
C0.D1 (n=11)
|
49.79 ng*hr/mL
Geometric Coefficient of Variation 61
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ
C1.D21 (n=5)
|
212.3 ng*hr/mL
Geometric Coefficient of Variation 24
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ
C0.D1 (n=11)
|
0.500 hours
Interval 0.5 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ
C1.D21 (n=8)
|
1.00 hours
Interval 0.5 to 3.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
Serum decay half-life is the time measured for the serum concentration to decrease by one half.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Serum Decay Half-life (t 1/2): MDZ
C0.D1 (n=11)
|
5.045 hours
Standard Deviation 1.7221
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Serum Decay Half-life (t 1/2): MDZ
C1.D21 (n=5)
|
7.764 hours
Standard Deviation 0.68475
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dosePopulation: N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=11 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Oral Clearance (CL/F): MDZ
C0.D1 (n=11)
|
20090 mL/hr
Geometric Coefficient of Variation 61
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Apparent Oral Clearance (CL/F): MDZ
C1.D21 (n=5)
|
4709 mL/hr
Geometric Coefficient of Variation 24
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline up to 12 cycles (cycle=21days)Population: RECIST response analysis set: all enrolled participants who had an adequate baseline tumor assessment, measureable disease and who started treatment. N=number of participants with evaluable data at observation.
Best response recorded from start of treatment (Tx) until disease progression. Complete response: disappearance of all target lesions. Partial response: ≥30% decrease in sum of longest dimensions (LD) of target lesions referencing baseline sum LD. Progressive disease: ≥20% increase in sum LD of target lesions from smallest sum LD recorded since Tx start or appearance of ≥1 new lesions. Stable disease: neither sufficient shrinkage to=PR nor sufficient increase to=PD during first 6 weeks after Tx start referencing smallest sum LD since Tx start.
Outcome measures
| Measure |
PF-00562271 5 mg BID
n=2 Participants
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 Participants
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 Participants
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 Participants
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 Participants
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=2 Participants
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 Participants
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=1 Participants
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.
|
PF-00562271 80 mg BID
n=3 Participants
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=8 Participants
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 105 mg BID
n=6 Participants
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=31 Participants
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
PF-00562271 150 mg BID
n=3 Participants
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=3 Participants
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=6 Participants
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=8 Participants
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
PF-00562271 100 mg BID (Expansion Cohort)
PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.
|
PF-00562271 125 mg BID (Expansion Cohort)
PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)
Complete response
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)
Partial response
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)
Stable disease
|
0 percentage of participants
|
1 percentage of participants
|
2 percentage of participants
|
2 percentage of participants
|
2 percentage of participants
|
0 percentage of participants
|
2 percentage of participants
|
0 percentage of participants
|
2 percentage of participants
|
2 percentage of participants
|
2 percentage of participants
|
11 percentage of participants
|
0 percentage of participants
|
1 percentage of participants
|
3 percentage of participants
|
1 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)
Progressive disease
|
2 percentage of participants
|
3 percentage of participants
|
1 percentage of participants
|
2 percentage of participants
|
1 percentage of participants
|
1 percentage of participants
|
2 percentage of participants
|
0 percentage of participants
|
1 percentage of participants
|
2 percentage of participants
|
4 percentage of participants
|
15 percentage of participants
|
3 percentage of participants
|
2 percentage of participants
|
2 percentage of participants
|
3 percentage of participants
|
—
|
—
|
|
Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)
Indeterminate
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
1 percentage of participants
|
0 percentage of participants
|
1 percentage of participants
|
0 percentage of participants
|
4 percentage of participants
|
0 percentage of participants
|
5 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
1 percentage of participants
|
4 percentage of participants
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)Population: Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.
Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; FAK is overexpressed in a variety of human cancers. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)Population: Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.
Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; MAPK regulates activities of several transcription factors. A defect in MAPK pathway leads to uncontrolled cell growth. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)Population: Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.
Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; SRC proto-oncogenes are regulators of growth and differentiation of eukaryotic cells and are implicated in development of human tumors. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose; on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)Population: Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.
Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.
Outcome measures
Outcome data not reported
Adverse Events
PF-00562271 5 mg BID
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
PF-00562271 10 mg BID
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
PF-00562271 15 mg BID
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
PF-00562271 25 mg BID
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
PF-00562271 35 mg BID
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
PF-00562271 45 mg BID
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
PF-00562271 60 mg BID
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
PF-00562271 75 mg BID
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
PF-00562271 80 mg BID
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
PF-00562271 100 mg BID
Serious events: 3 serious events
Other events: 10 other events
Deaths: 0 deaths
PF-00562271 105 mg BID
Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths
PF-00562271 125 mg BID
Serious events: 12 serious events
Other events: 33 other events
Deaths: 0 deaths
PF-00562271 150 mg BID
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
PF-00562271 125 mg QD
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
PF-00562271 175 mg QD
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
PF-00562271 225 mg QD
Serious events: 3 serious events
Other events: 8 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
PF-00562271 5 mg BID
n=2 participants at risk
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 participants at risk
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 participants at risk
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 participants at risk
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 participants at risk
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 participants at risk
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 participants at risk
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=1 participants at risk
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.
|
PF-00562271 80 mg BID
n=3 participants at risk
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=10 participants at risk
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 105 mg BID
n=6 participants at risk
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=33 participants at risk
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 150 mg BID
n=3 participants at risk
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=4 participants at risk
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=7 participants at risk
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=8 participants at risk
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Pyrexia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Headache
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Ureteral disorder
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Hypertension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Hypotension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
Other adverse events
| Measure |
PF-00562271 5 mg BID
n=2 participants at risk
PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).
|
PF-00562271 10 mg BID
n=4 participants at risk
PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).
|
PF-00562271 15 mg BID
n=3 participants at risk
PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).
|
PF-00562271 25 mg BID
n=4 participants at risk
PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).
|
PF-00562271 35 mg BID
n=3 participants at risk
PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).
|
PF-00562271 45 mg BID
n=4 participants at risk
PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).
|
PF-00562271 60 mg BID
n=4 participants at risk
PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).
|
PF-00562271 75 mg BID
n=1 participants at risk
PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.
|
PF-00562271 80 mg BID
n=3 participants at risk
PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).
|
PF-00562271 100 mg BID
n=10 participants at risk
PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 105 mg BID
n=6 participants at risk
PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).
|
PF-00562271 125 mg BID
n=33 participants at risk
PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort \[E1 or E2\]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.
|
PF-00562271 150 mg BID
n=3 participants at risk
PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).
|
PF-00562271 125 mg QD
n=4 participants at risk
PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).
|
PF-00562271 175 mg QD
n=7 participants at risk
PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).
|
PF-00562271 225 mg QD
n=8 participants at risk
PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Candidiasis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Blood and lymphatic system disorders
Microcytic anaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Ear and labyrinth disorders
Dysacusis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Endocrine disorders
Endocrine disorder
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Eye disorders
Eye pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Eye disorders
Eye pruritus
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Eye disorders
Photopsia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Eye disorders
Vision blurred
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
2/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
2/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.1%
4/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Breath odour
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
18.2%
6/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
40.0%
4/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
4/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
30.3%
10/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
57.1%
4/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
75.0%
6/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Lip swelling
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Nausea
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
75.0%
3/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
1/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
40.0%
4/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
3/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
22/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
4/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
7/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
8/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Oral discomfort
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Salivary hypersecretion
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
1/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
60.0%
6/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
3/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
45.5%
15/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
75.0%
3/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
57.1%
4/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
87.5%
7/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Asthenia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Catheter site pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Chest discomfort
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Chest pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Chills
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Face oedema
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Facial pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Fatigue
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
4/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
1/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
30.0%
3/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
3/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
48.5%
16/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
4/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
42.9%
3/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
75.0%
6/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Influenza like illness
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Injection site rash
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Local swelling
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Localised oedema
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Oedema
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Oedema peripheral
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
75.0%
3/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
40.0%
4/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
3/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
36.4%
12/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
42.9%
3/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
2/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
General disorders
Pyrexia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
30.0%
3/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Hepatobiliary disorders
Hepatic pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Cystitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Influenza
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Viral diarrhoea
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Viral infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Infections and infestations
Wound infection
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Injury, poisoning and procedural complications
Periorbital haematoma
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Blood amylase increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Blood prolactin increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Body temperature increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Cardiac murmur
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Oxygen saturation decreased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Investigations
Weight decreased
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
27.3%
9/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
4/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Fluid retention
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
2/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Metabolism and nutrition disorders
Metabolic alkalosis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
24.2%
8/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Coccydynia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Hot flush
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.1%
4/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
9.1%
3/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic fracture
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Dizziness
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
30.0%
3/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
18.2%
6/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
66.7%
2/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
42.9%
3/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
4/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
15.2%
5/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Headache
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
1/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
40.0%
4/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
3/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
42.4%
14/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
100.0%
3/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
85.7%
6/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
4/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Hyperaesthesia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Migraine
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Parosmia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Sinus headache
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Syncope
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Nervous system disorders
Tremor
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Depression
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Dysuria
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Reproductive system and breast disorders
Breast disorder
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
15.2%
5/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
50.0%
2/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
2/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
18.2%
6/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Hypertension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
20.0%
2/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory tract congestion
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
50.0%
1/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
12.5%
1/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Papule
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
6.1%
2/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Red man syndrome
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Social circumstances
Corrective lens user
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Flushing
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
1/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Hypotension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
10.0%
1/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
16.7%
1/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
24.2%
8/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
33.3%
1/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
37.5%
3/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
3.0%
1/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
28.6%
2/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
25.0%
2/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
|
Vascular disorders
Subclavian vein thrombosis
|
0.00%
0/2 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/1 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/10 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/6 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/33 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/3 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/4 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
14.3%
1/7 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
0.00%
0/8 • Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER